Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00537745 · ClinicalTrials.gov registry record · Phase 4
Vivitrol for Reducing Driving While Impaired Behavior Among Repeat Offenders
A Phase 4 study, sponsored by Pacific Institute for Research and Evaluation.
- Completed
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT00537745: Completed Phase 4 study, sponsored by Pacific Institute for Research and Evaluation.
NCT00537745 is a Phase 4 study that has completed, run by Pacific Institute for Research and Evaluation. The registered enrollment target is 14 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00537745, a Phase 4 study, has completed, sponsored by Pacific Institute for Research and Evaluation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Vivitrol is effective at reducing attempts to drive after drinking among repeat driving while intoxicated (DWI) offenders with Ignition Interlock devices.
Primary Outcome
This was measured as Percent of days with an Interlock report of "Failure to Start" due to alcohol pre/on medication and 6 months post medication.
Interventions
- DRUG Vivitrol (Medication Therapy)
- OTHER Medication Management Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2007-04 |
| Est. Completion | 2009-05 |
| Phase | Phase 4 |
What the finished NCT00537745 record still lists
NCT00537745 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Vivitrol (Medication Therapy) is the first listed.
NCT00537745 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00537745 about?
NCT00537745 is a clinical study titled "Vivitrol for Reducing Driving While Impaired Behavior Among Repeat Offenders". The purpose of this study is to determine whether Vivitrol is effective at reducing attempts to drive after drinking among repeat driving while intoxicated (DWI) offenders with Ignition Interlock devices.
What is the current status of trial NCT00537745?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2007-04. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00537745?
The interventions under investigation include: Vivitrol (Medication Therapy) (DRUG), Medication Management Therapy (OTHER).
Who is sponsoring clinical trial NCT00537745?
This trial is sponsored by Pacific Institute for Research and Evaluation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00537745's enrollment target sits among peer trials
14 1901st of 2000 higher than 91 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia